Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Sci ; 94(1): 119-24, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12708485

ABSTRACT

We have discovered a novel topoisomerase II (topo II) poison, ER-37328 (12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione hydrochloride), which shows potent tumor regression activity against Colon 38 cancer inoculated s.c. Here, we describe studies on the cell-killing activity against a panel of human cancer cell lines and the antitumor activity of ER-37328 against human tumor xenografts. In a cell-killing assay involving 1-h drug treatment, ER-37328 showed more potent cell-killing activity (50% lethal concentrations (LC50s) ranging from 2.9 to 20 microM) than etoposide (LC50s>60 microM) against a panel of human cancer cell lines. ER-37328 induced double-stranded DNA cleavage, an indicator of topo II-DNA cleavable complex formation, within 1 h in MX-1 cells, and the extent of cleavage showed a bell-shaped relationship to drug concentration, with the maximum at 2.5 microM. After removal of the drug (2.5 microM) at 1 h, incubation was continued in drug-free medium, and the amount of cleaved DNA decreased. However, at 10 microM, which is close to the LC50s against MX-1 cells, DNA cleavage was not detected immediately after 1-h treatment, but appeared and increased after drug removal. This result may explain the potent cell-killing activity of ER-37328 in the 1-h treatment. In vivo, ER-37328 showed potent tumor regression activity against MX-1 and NS-3 tumors. Moreover, ER-37328 had a different antitumor spectrum from irinotecan or cisplatin against human tumor xenografts. In conclusion, ER-37328 is a promising topo II poison with strong cell killing activity in vitro and tumor regression activity in vivo, and is a candidate for the clinical treatment of malignant solid tumors.


Subject(s)
Antineoplastic Agents/therapeutic use , Carbazoles/therapeutic use , Enzyme Inhibitors/therapeutic use , Neoplasm Proteins/antagonists & inhibitors , Pyrimidines/therapeutic use , Topoisomerase II Inhibitors , Adenocarcinoma/pathology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Breast Neoplasms/pathology , Carbazoles/pharmacology , Colonic Neoplasms/pathology , DNA Damage , DNA, Neoplasm/analysis , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Etoposide/therapeutic use , Female , Humans , Lung Neoplasms/pathology , Macromolecular Substances , Mice , Mice, Inbred BALB C , Mice, Nude , Protein Binding/drug effects , Pyrimidines/pharmacology , Stomach Neoplasms/pathology , Tumor Cells, Cultured/drug effects , Xenograft Model Antitumor Assays
2.
Mol Cancer Ther ; 2(1): 59-64, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12533673

ABSTRACT

12,13-Dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c] pyrimido[5,6,1-jk] carbazole-4,6,10(5H,11H)-trione hydrochloride (ER-37328) is a novel topoisomerase II poison with potent tumoricidal activity against solid tumor cells both in vitro and in vivo. Here, we describe studies on the effects of ER-37328 on the primary tumor, liver metastasis, and survival in a murine Colon 38 orthotopic transplantation model. When ER-37328 (10 mg/kg) was administered i.v. at 11 days or 20 days after transplantation, strong regression of the primary tumor was observed on both administration schedules. On the later schedule, ER-37328 completely blocked liver metastasis, whereas the mean number of metastases in the control group was 23.9. To examine the antitumor activity against Colon 38 at the liver in more detail, ER-37328 was administered to mice that had received an inoculation of Colon 38 tumor into the liver. ER-37328 showed strong tumor-regression activity against Colon 38 growing in the liver. In addition, administration of ER-37328 on a schedule of every 7 days four times caused a significant increase of 79% in life span in the orthotopic transplantation model, calculated by using mean survival times. Pharmacokinetic study revealed that ER-37328 was highly distributed to the tumor and organs. The ratios of the area under the concentration-time curves of ER-37328 in the tumor, lung, liver, and kidney versus plasma were 81, 77, 47, and 40, respectively. This high distribution to the tumor and liver may explain the potent antitumor activity of ER-37328 against Colon 38 tumor in the liver. In conclusion, the topoisomerase II poison ER-37328 is a promising candidate for clinical application against colon cancer.


Subject(s)
Carbazoles/therapeutic use , Colonic Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Pyrimidines/therapeutic use , Animals , Cell Division/drug effects , Colonic Neoplasms/pathology , Etoposide/therapeutic use , Female , Humans , Liver Neoplasms/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred Strains , Neoplasm Metastasis , Survival Analysis , Time Factors , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL
...